Publications by authors named "Biazi R Assis"
Article Synopsis
- Epidemiological cancer research is crucial for understanding tumors and developing new treatments, yet Brazil has low participation in clinical trials, with only 2.2% of ongoing trials available despite 625,000 new cancer cases in 2022.
- An online survey of 109 Brazilian physicians, mainly oncologists, aimed to assess their involvement in research and identify barriers to conducting clinical trials.
- Results showed that while 89.9% of physicians found clinical trial participation important, 31.2% invite less than 1% of their patients to join trials, mainly due to a shortage of available studies and qualified personnel.
Purpose: Breast cancer is the most common malignancy in Brazilian women, with 66,280 new cases in 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]). The trastuzumab biosimilar was the first oncology biosimilar approved in Brazil for HER2-positive breast cancer treatment. This study aimed to assess the current level of knowledge of biosimilars, comfort of use, extrapolation indications, and switching of practices among oncologists in Brazil.
View Article and Find Full Text PDFSentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidence.
Acta Cir Bras
July 2021
Purpose: To reduce false-negative rates (FNR) in sentinel lymph node biopsy (SLNB) of clinically positive (cN+) axilla in patients undergoing neoadjuvant chemotherapy (NAC). The removal of three or more lymph nodes with dual-tracer mapping including a radioisotope was used. However, in the Brazilian Unified Health System, the radioisotope tracer is not feasible in some hospitals.
View Article and Find Full Text PDF